Our findings demonstrate that SCLC-specific molecular features—including dynamic TMB trajectories, MYC amplification status, and distinct genomic alteration profiles—may critically influence immunotherapy sensitivity. This evidence concerns the gene MYC and small cell lung carcinoma.